N@N

NEW YORK--([ BUSINESS WIRE ])--aThe race is on for a better mammograma states the December 19^th headline in Fortune Magazineas (online) story by Sierra Jiminez. The story then beginsa"and endsa"with the breakthrough work of Edward R. Flynn, PhD, of Manhattan Scientifics Inc. (OTCBB: MHTX). [ Manhattan Scientifics ] is focused on the technology transfer and commercialization of disruptive technologies in the nano medicine space, including Dr. Flynn's early detection technology.

"The race is on for a better mammogram"

Dr. Flynn has spent 10 years perfecting an early detection technology that can spot cancerous tumor years earlier than a mammogram can, with no radiation and 100% specificity. Dr. Flynnas technology uses tiny, iron oxide nanoparticles, attached to known breast cancer antibodiesa"which can only bind to breast cancers. The bound nanoparticles create a magnetic signal that is detected by something called a SQUID machine; Dr. Flynnas patented technology enables the technician to see the cancer with as few as 100,000 cells. A mammogram typically sees a cancer when it is 100 million cells or larger.

The FORTUNE article points out that Dr. Flynnas technologyas potential for early detection has attracted the attention of MD Anderson Cancer Center in Houston, noting that, aJohn Hazle of MD Anderson Cancer Center agrees. In fact, that's the reason, he says, MD Anderson signed on for a pre-clinical evaluation of Edward Flynn's magnetic nano-particle technology in August this year.a

The article can be read in its entirety at: [ http://tech.fortune.cnn.com/2011/12/19/mammogram/ ]

About Manhattan Scientifics

Manhattan Scientifics Inc. ([ www.mhtx.com ]) is located in New Mexico, New York and Montreal. It is focused on technology transfer and commercialization of disruptive technologies in the nano medicine space. The company is presently developing commercial medical prosthetics applications for its ultra fine grain metals and plans to commercialize the cancer research work and nano medical applications developed by Senior Scientific LLC, a unit of the Company.

Forward-looking statement

This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.